NCT05243342

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

About the study

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Life expectancy of at least 12 weeks
Measurable disease, as defined by the protocol
Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody
Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment

EXCLUSION CRITERIA

Exclusion Criteria:

Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol
Prior allogeneic stem cell or solid organ transplantation
Autologous stem cell transplantation within 100 days prior to initiation of study treatment
Significant cardiovascular disease
Known clinically significant liver disease
Active or history of autoimmune disease or immune deficiency
Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration
Primary or secondary plasma cell leukemia
Current CNS involvement by MM

Other protocol defined inclusion/exclusion criteria may apply